Eli Lilly's $3.5B Fogelsville Plant to Produce Retatrutide, Europe Rollout Late 2026
LLY•President Trump's highlight of Eli Lilly's $3.5 billion Fogelsville, Pennsylvania facility underscores expansion of manufacturing capacity for next-generation weight-loss medicines. The site will create 850 permanent jobs and about 2,000 construction roles, and Retatrutide is scheduled for launch in Europe and the United Kingdom in late 2026.
1. $3.5B Fogelsville Investment
Eli Lilly announced in January a $3.5 billion investment for a state-of-the-art injectable medicine and device manufacturing facility in Fogelsville, Pennsylvania. The site is designed to produce next-generation weight-loss medicines such as Retatrutide and create 850 high-value positions plus roughly 2,000 construction jobs, with operations anticipated to begin in 2031.
2. Presidential Spotlight and Investor Response
President Trump spotlighted the Fogelsville facility during a jobs-focused address in Pennsylvania, citing Lilly’s new factory as evidence of manufacturing momentum and economic growth. Shares of Eli Lilly rose 0.4% following the mention, reflecting investor optimism around the company’s expansion and weight-loss drug prospects.
3. Pipeline Advances and Global Rollout
Phase 3 results showed Retatrutide reduced obstructive sleep apnea severity by 60.6% and knee osteoarthritis pain by 73.1% in adults with obesity, with prior studies demonstrating an average 28% body weight reduction. Lilly plans to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027, targeting telehealth channels while pursuing public reimbursement.
